Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression

Roth, Carina; Pantel, Klaus; Müller, Volkmar; Rack, Brigitte; Kasimir-Bauer, Sabine; Janni, Wolfgang; Schwarzenbach, Heidi

doi:10.1186/1471-2407-11-4

Table 1 Patient characteristics and their correlations with the nucleic acid levels and protease/caspase activities in blood

From: Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression

	Patients (%)	Nucleosome levels	DNA levels	Protease activities	Caspase activities
		Mean values ± Standard Deviation Median Percentiles (10^th, 90^th)
Breast Cancer Patients
Total	63
Age	56 years (range 34 - 82 years)
Distant metastasis
^£ M0	31 (49.2)	¹ 878 ± 123 851 767, 1078	² 8241 ± 701 8293 7232, 9195	³ 22218 ± 12236 12682 10401, 35242	35895 ± 62242 7990 2550, 134240
^$ M1	32 (50.8)	¹ 894 ± 112 841 812, 1076	² 9933 ± 4430 8756 7237, 16836	³ 32337 ± 9021 33326 13573, 45296	11486 ± 9167 8570 4718, 31628
^# Tumor stage
pT1-2	29 (53.7)	866 ± 31 858 822, 1058	8352 ± 728 8528 6559, 10246	⁴ 11042 ± 750 10966 10412, 41664	⁵ 5386 ± 2042 5545 2655, 24540
pT3-4	25 (46.3)	829 ± 125 769 763, 1079	7690 ± 389 7564 7240, 19519	⁴ 30439 ± 10052 34378 12258, 42790	⁵ 66341 ± 93967 26670 2736, 181806
^# Lymph node metastasis
N0	13 (23.6)	⁶ 814 ± 80 769 767, -	8027 ± 518 8011 7517, -	26649 ± 14005 34216 10488, -	19370 ± 17547 12350 6420, -
N1-3	42 (76.4)	⁶ 860 ± 85 844 781, 1079	8079 ± 737 8149 6901, 10904	17366 ± 10972 11167 10408, 43572	34821 ± 74658 6890 2613, 66132
^# Grading
I-II	25 (46.3)	813 ± 39 827 762, 1057	7914 ± 896 7885 6807, 9056	18737 ± 11916 11964 10001, 37741	47295 ± 99075 7570 2544, 225815
III	29 (53.7)	878 ± 98 878 768, 1118	8183 ± 494 8137 6984, 15827	19819 ± 12451 11165 10469, 39564	19671 ± 27313 6655 2907, 51685
^# Estrogen receptor
positive	41 (68.3)	846 ± 92 837 767, 1078	7924 ± 719 7868 7185, 9298	20468 ± 12204 11964 10356, 45976	38382 ± 77766 7570 2547, 97376
negative	19 (31.7)	861 ± 65 885 767, -	8428 ± 445 8351 6357, -	16574 ± 11766 10827 10423, -	14330 ± 16701 6655 4670, -
^# Progesterone receptor
positive	36 (60)	825 ± 44 830 768, 1010	7927 ± 796 8124 6949, 9039	17617 ± 11811 11163 10135, 46261	7317 ± 4533 7152 2532, 25178
negative	24 (40)	875 ± 107 865 764, 1144	8209 ± 561 8149 6805, 18757	21094 ± 12382 12682 10456, 35961	55703 ± 90000 6890 2910, 164920
^# HER2
positive	23 (39.7)	855 ± 88 844 767, 1078	8148 ± 628 8149 7249, 9183	19548 ± 11973 11167 10312, 39775	35294 ± 74482 6890 2544, 114262
negative	35 (60.3)	832 ± 70 823 772, 1193	7774 ± 919 8011 6397, 24618	18650 ± 13486 11245 10564, 45011	17637 ± 18799 7150 4765, 38669
Benign Breast Tumor Patients
Total	20
Age	49 years (range 18 - 79 years)
		831 ± 102 794 768, 922	9306 ± 1156 8837 7611, 11240	16837 ± 5295 14845 14697, 30293	5580 ± 4186 4610 2714, 9307
Leukocytes
<10.7/nl	16 (80)	808 ± 61 788 768, -	9471 ± 1068 9191 8496, -	18044 ± 6780 15016 14689, -	4957 ± 2485 4550 2710, -
>10.7/nl	1 (5)	1228 - -, -	11626 - -, -	- - -, -	3010 - -, -
CRP
<0.5 mg/dl	11 (55)	780 ± 16 780 768, -	9191 ± 235 9191 9024, -	24387 ± 10441 24387 17004, -	5835 ± 4363 5835 2750, -
>0.5 mg/dl	5 (25)	823 ± 72 795 772, -	9611 ± 1343 9281 8496, -	14873 ± 197 14831 14689, -	4518 ± 1782 4550 2710, -
CEA
<3.5 ng/ml	15 (75)	815 ± 65 791 768, -	9383 ± 1169 9024 8496, -	18715 ± 7354 15141 14771, -	5292 ± 2622 5820 2710, -
>3.5 ng/ml	1 (5)	772 - -, -	9913 - -, -	14689 - -, -	3280 - -, -
CA-125
<65 U/ml	15 (75)	808 ± 61 788 768, -	9471 ± 1068 9191 8496, -	18044 ± 6780 15016 14689, -	4957 ± 2485 4550 2710, -
>65 U/ml	2 (10)	1011 ± 307 - -, -	9926 ± 2404 - -, -	14799 - -, -	3735 ± 1025 - -, -
Healthy Women
Total	28
Age	41 years (range 21 - 67 years)
		726 ± 50 725 715, 809	7747 ± 678 7641 7175, 8801	21133 ± 8028 14996 13166, 30500	5182 ± 2379 5075 3064, 9277

^£M0, patients with localized breast cancer
^$M1, patients with metastatic breast cancer
^#parameters of M0 patients
¹p = 0.01, ²p = 0.04, ³p = 0.008, ⁴*p = 0.009, ⁵p = 0.009, ⁶p = 0.004
p values as determined by Mann and Whitney-U test (in bold)
*p values as determined by T test (in bold)

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us